Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma

Neurology

Volumn 81, Issue 1, 2013, Pages 84-92

  Doolittle, Nancy D ^a   Korfel, Agnieszka ^b   Lubow, Meredith A ^a   Schorb, Elisabeth ^c   Schlegel, Uwe ^c   Rogowski, Sabine ^c   Fu, Rongwei ^a   Dósa, Edit ^e   Illerhaus, Gerald ^c   Kraemer, Dale F ^d   Muldoon, Leslie L ^a   Calabrese, Pasquale ^f   Hedrick, Nancy ^a   Tyson, Rose Marie ^a   Jahnke, Kristoph ^b   Maron, Leeza M ^a   Butler, Robert W ^a   Neuwelt, Edward A ^a,g  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNIVERSITY OF BASEL   (Switzerland)

^g PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVOR; CHILD; COGNITION; DRUG MEGADOSE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; VERBAL MEMORY;

ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; COGNITION; HUMANS; LYMPHOMA; METHOTREXATE; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84881228054     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318297eeba     Document Type: Article

References (35)

1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-1288.
2. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate- based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570-4574.
3. Morris PG, Abrey LE. Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009;8:581-592.
4. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18:3144-3150.
5. Ferreri AJ, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003; 21:2407-2414. 6.
6. Harder H, Holtel H, Bromberg JE, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004;62:544-547. 7.
7. Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18:1145-1151. 8.
8. Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 2012;14:101-108. 9.
9. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment- induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004;62: 451-456. 10.
10. Fliessbach K, Urbach H, Helmstaedter C, et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 2003;60:563-568. 11.
11. Fliessbach K, Helmstaedter C, Urbach H, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005; 64:1184-1188. 12.
12. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multiinstitutional experience. J Clin Oncol 2009;27:3503-3509. 13.
13. Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K. Primary CNS lymphoma in immunocompetent patients. Oncologist 2009;14:526-539. 14.
14. Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010;67:182-189. 15.
15. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, noninferiority trial. Lancet Oncol 2010;11:1036-1047. 16.
16. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006;24:1305-1309. 17.
17. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004;62: 548-555. 18.
18. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 2005;26:258-265. 19.
19. Weller M. Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials. Neuro Oncol 2011;13:565. 20.
20. Wechsler D. Wechsler Adult Intelligence Scale (WAIS-III), 3rd ed. San Antonio: Harcourt Brace & Co; 1997. 21.
21. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Tucson: Neuropsychology Press; 1985. 22.
22. Schretlen D, Bobholz JH, Brandt J. Development and psychometric properties of the brief test of attention. Clin Neuropsychol 1996;10:80-89. 23.
23. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 1998;12:43-55. 24.
24. Heaton RK, Grant I, Matthews CG. Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographic Corrections, Research Findings and Clinical Applications. Odessa: Psychological Assessment Resources; 1991. 25.
25. Heaton RK, Miller SW, Taylor MJ, Grant I. Revised Comprehensive Norms for an Extended Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults (HRB). Lutz: Psychological Assessment Resources; 2004. 26.
26. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22:157-165. 27.
27. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60; discussion 60-61. 28.
28. AaronsonNK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. 29.
29. Fayers P, Aaronson NK, Bjordal K, Curran D, Groenvold M. The EORTC QLQ-c30 Scoring Manual, 3rd ed. Brussels, Belgium: European Organization for Research and Treatment of Cancer; 2001. 30.
30. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3:159-168. 31.
31. Abrey LE. The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors. J Neurooncol 2012;108:285-290. 32.
32. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol 2011;29: 2397-2404. 33.
33. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-4735. 34.
34. Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduceddose radiotherapy. J Neurooncol 2009;91:315-321. 35.
35. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012;30:274-281.